PneumoNP
Nanotherapeutics to Treat Antibiotic Gram-Negative Pneumonia Infections
- Description
Infections due to antibiotic resistant Gram-negative bacteria are one of the major issues currently affecting global health, largely due to a lack of effective antibiotic therapy for this type of infection. The PneumoNP team will therefore specifically focus its attention on the pathogen Klebsiella pneumoniae, a global cause of antibiotic resistant infections. PneumoNP will generate: a new inhalable drug system composed of a nanotherapeutic system combining an antimicrobial peptide or active pharmaceutical ingredient (API) and a nanocarrier; a new aerosol technology specifically developed for the nanotherapeutic system; an innovative efficiency-efficacy test to follow-up the treatment; a new diagnostic kit for the rapid and multiplex identification of bacteria causing respiratory infections.
- Coordinator
Related News
- Programme
- FP7
- Duration
- 48 months (January 2014 - December 2017)
- Project funding
- € 5,682,351.00
- Project partners
- 11
- Technology readiness level
- 2-4